Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Table 1 Patient characteristics

Patient no.	Year of dg	Gender	Age at dg	Sokal score	Treatment	Treatment response
1.	1996	F	45	7.44	HU, 11/96 IFN, 6/2002 IM, 5/2005 DAS	No CgR
2.	1998	F	56	1.37	HU, 3/99 IFN, 04/2002 IM, 08/2006 DAS	Min CgR
3.	2010	M	68	1.61	HU, 3/2010 IM, 12/2010 NIL, 6/2011 DAS	Min CgR
4.	2008	M	58	1.39	HU, 7/2008 IM, 6/2009 DAS, 3/2010 alloHSCT	No CgR
5.	2005	M	48	0.93	HU, 11/2005 IM, 2/2006 IM + IFN	CMR
6.	2005	M	58	0.77	11/2005 IM	CMR
7.	2004	M	55	0.69	HU, 10/2004 IM, 3/2005 IM + IFN	CMR
8.	2006	F	53	0.68	HU, 1/2007 IM	CMR
9.	2006	M	52	0.85	HU, 1/2007 IM	MMR

In all non-responder patients (patients 1–4) the treatment response to imatinib was failure based on the European Leukemia Net (ELN) criteria [3] (no or minimal cytogenetic response to imatinib within 12 months after the start of therapy). These patients were subsequently treated with other TKIs (dasatinib/nilotinib), but no cytogenetic responses were achieved with 2nd generation TKIs either, confirming these patients to be non-responders to multiple TKIs. Patients in the responder group (patients 5–9) fulfilled the optimal response to imatinib based on ELN criteria. Abbreviations: no number, dg diagnosis, HU hydroxyurea, IFN interferon, IM imatinib, DAS dasatinib, NIL nilotinib, alloHSCT allogeneic hematopoietic stem cell transplantation, CgR cytogenetic response, min minimal, CMR complete molecular response, MMR major molecular response.

ISSN: 1755-8166